2010年，上市许可申请数据下降的药品包含新药和仿制药，仿制药在完成申请方面下降特别明显。
For 2010, the decline in MA applications encompasses both new products and generics and is particularly marked in finalized applications.
2009年，欧洲药物管理局分别启动95例和完成125例上市许可申请，相比2010年则分别是75和41例。
In 2009, EMA started and finalized 95 and 125 MA applications, respectively, compared with only 75 and 41 in 2010.
2007年，欧洲药物管理局分别启动和完成90和65例上市许可申请，而到2008年这一数据增加到了103和72例。
In 2007, EMA started and finalized 90 and 65 MA applications, respectively, and these Numbers increased in 2008 to 103 and 72 applications.
2007年，欧洲药物管理局分别启动和完成90和65例上市许可申请，而到2008年这一数据增加到了103和72例。
In 2007, EMA started and finalized 90 and 65 MA applications, respectively, and these Numbers increased in 2008 to 103 and 72 applications.
应用推荐